>By packaging lipid nanoparticles with elements that decrease the fibrous nature of solid tumors, researchers can deliver CRISPR therapies in a more efficient manner.
>
>In a paper recently published in Nature Nanotechnology, Siegwart and his team developed a dual approach using LNPs equipped with tools that allow them to access and modify the tumor.4 The researchers packaged the LNPs with a CRISPR-Cas9 system that genetically modified and disrupted PD-L1 gene expression. PD-L1 overexpression inhibits T cell infiltration within the tumor microenvironment, so deactivating the gene allows immune cells to access the tumor. To grant the CRISPR system and immune cells tumor access, the LNP also included siRNA that targeted and reduced the expression of focal adhesion kinase (FAK), which diminished the density of the extracellular matrix surrounding the tumor.

This is really good news. One of the biggest challenges with mRNA and CRISPR therapies for cancer treatments is penetrating solid tumors.